AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%

AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes.

The company described the results as striking, noting that the trial outcomes exceeded Wall Street expectations for efficacy.

Following the announcement, AbCellera’s share price rose roughly 31% by mid-morning on the day of the release.

The data come from a mid-stage study, and the company indicated that further development will continue as it moves toward later-stage trials.